Cabozantinib in hepatocellular cancer: from preclinical experiments to observational studies-Reference-Cited by-同舟云学术

Cabozantinib in hepatocellular cancer: from preclinical experiments to observational studies

Published:2022-12-20 Issue:4 Volume:12 Page:41-51
ISSN:2686-9594
Container-title:Pelvic Surgery and Oncology
language:
Short-container-title:Onkol. koloproktol.

Author:

Fedyanin M. Yu.¹^ORCID

Affiliation:

1. N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; Moscow Multidisciplinary Clinical Center "Kommunarka", Department of Health of Moscow; National Medical and Surgical Center named after N.I. Pirogov, Ministry of Health of Russia

Publisher

Publishing House ABV Press

Subject

General Medicine

Reference68 articles.

1. Xiang Q., Chen W., Ren M. et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res 2014;20(11):2959–70. DOI:10.1158/1078-0432.CCR-13-2620

2. Rimassa L., Abbadessa G., Personeni N. et al. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget 2016;7(45):72622–33. DOI:10.18632/oncotarget.11621

3. Rimassa L., Assenat E., Peck-Radosavljevic M. et al. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol 2018;19(5):682–93. DOI:10.1016/S1470-2045(18)30146-3

4. Trojan J. Cabozantinib for the treatment of advanced hepatocellular carcinoma: current data and future perspectives. Drugs 2020;80:1203–10. DOI:10.1007/s40265-020-01361-5

5. Abou-Alfa G.K., Meyer T., Cheng A.L. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379(1):54–63.